Show simple item record

dc.contributor.authorRegan, Men
dc.contributor.authorNeven, Pen
dc.contributor.authorGiobbie-Hurder, Aen
dc.contributor.authorGoldhirsch, Aen
dc.contributor.authorEjlertsen, Ben
dc.contributor.authorMauriac, Len
dc.contributor.authorForbes, Jen
dc.contributor.authorSmith, Ien
dc.contributor.authorLáng, Ien
dc.contributor.authorWardley, Andrew Men
dc.contributor.authorRabaglio, Men
dc.contributor.authorPrice, Ken
dc.contributor.authorGelber, Ren
dc.contributor.authorCoates, Aen
dc.contributor.authorThürlimann, Ben
dc.date.accessioned2012-02-29T13:07:13Z
dc.date.available2012-02-29T13:07:13Z
dc.date.issued2011-11
dc.identifier.citationAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. 2011, 12 (12):1101-8 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid22018631
dc.identifier.doi10.1016/S1470-2045(11)70270-4
dc.identifier.urihttp://hdl.handle.net/10541/213550
dc.description.abstractPostmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.
dc.language.isoenen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshAromatase Inhibitors
dc.subject.meshAustralia
dc.subject.meshBreast Neoplasms
dc.subject.meshCross-Over Studies
dc.subject.meshDisease-Free Survival
dc.subject.meshDouble-Blind Method
dc.subject.meshEurope
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshNeoplasms, Second Primary
dc.subject.meshNew Zealand
dc.subject.meshNitriles
dc.subject.meshNorth America
dc.subject.meshPostmenopause
dc.subject.meshProportional Hazards Models
dc.subject.meshReceptors, Steroid
dc.subject.meshRisk Factors
dc.subject.meshSelective Estrogen Receptor Modulators
dc.subject.meshSouth Africa
dc.subject.meshSouth America
dc.subject.meshTamoxifen
dc.subject.meshTime Factors
dc.subject.meshTreatment Outcome
dc.subject.meshTriazoles
dc.subject.meshTumor Markers, Biological
dc.titleAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.en
dc.typeArticleen
dc.contributor.departmentInternational Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.en
dc.identifier.journalLancet Oncologyen
html.description.abstractPostmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.


Files in this item

This item appears in the following Collection(s)

Show simple item record